These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21265873)

  • 21. Early life voiding dysfunction leads to lower urinary tract dysfunction through alteration of muscarinic and purinergic signaling in the bladder.
    Iguchi N; Malykhina AP; Wilcox DT
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1320-F1328. PubMed ID: 30089034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo measurement by [3H]Tamsulosin of alpha1 adrenoceptors in rat tissues in relation to the pharmacokinetics.
    Yamada S; Ohkura T; Deguchi Y; Kimura R
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1575-83. PubMed ID: 10336555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs].
    Nagao M; Kaneko S; Hirota T; Isogai M; Shimizu H
    Nihon Yakurigaku Zasshi; 1999 Mar; 113(3):157-66. PubMed ID: 10347840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The concept of uroselectivity.
    Andersson KE
    Eur Urol; 1998; 33 Suppl 2():7-11. PubMed ID: 9556190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.
    McNamara A; Pulido-Rios MT; Sweazey S; Obedencio GP; Thibodeaux H; Renner T; Armstrong SR; Steinfeld T; Hughes AD; Wilson RD; Jasper JR; Mammen M; Hegde SS
    Eur J Pharmacol; 2009 Mar; 605(1-3):145-52. PubMed ID: 19168050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of vibegron, a novel β
    Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T
    Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.
    Williams TJ; Blue DR; Daniels DV; Davis B; Elworthy T; Gever JR; Kava MS; Morgans D; Padilla F; Tassa S; Vimont RL; Chapple CR; Chess-Williams R; Eglen RM; Clarke DE; Ford AP
    Br J Pharmacol; 1999 May; 127(1):252-8. PubMed ID: 10369480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo.
    Hegde SS; Choppin A; Bonhaus D; Briaud S; Loeb M; Moy TM; Loury D; Eglen RM
    Br J Pharmacol; 1997 Apr; 120(8):1409-18. PubMed ID: 9113359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
    Gillberg PG; Sundquist S; Nilvebrant L
    Eur J Pharmacol; 1998 May; 349(2-3):285-92. PubMed ID: 9671109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive and mood side effects of lower urinary tract medication.
    Muderrisoglu AE; Becher KF; Madersbacher S; Michel MC
    Expert Opin Drug Saf; 2019 Oct; 18(10):915-923. PubMed ID: 31373245
    [No Abstract]   [Full Text] [Related]  

  • 33. Urinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral Ligation.
    Ito Y; Kuraoka S; Endo S; Takahashi A; Onoue S; Yamada S
    J Pharmacol Exp Ther; 2017 Jan; 360(1):69-74. PubMed ID: 27831487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.
    Ney P; Pandita RK; Newgreen DT; Breidenbach A; Stöhr T; Andersson KE
    BJU Int; 2008 Apr; 101(8):1036-42. PubMed ID: 18279452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.
    Maruyama S; Oki T; Otsuka A; Shinbo H; Ozono S; Kageyama S; Mikami Y; Araki I; Takeda M; Masuyama K; Yamada S
    J Urol; 2006 Jan; 175(1):365-9. PubMed ID: 16406943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
    Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
    BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
    Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
    Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
    Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction.
    Ruggieri MR; Braverman AS; Pontari MA
    J Urol; 2005 Nov; 174(5):1743-8. PubMed ID: 16217275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors.
    Frazier EP; Peters SL; Braverman AS; Ruggieri MR; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):449-62. PubMed ID: 18060543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.